-
公开(公告)号:US20130053397A1
公开(公告)日:2013-02-28
申请号:US13696362
申请日:2011-05-05
申请人: James Brackley, III , Joelle Lorraine Burgess , Seth Grant , Neil Johnson , Steven D. Knight , Louis Lafrance , William H. Miller , Kenneth Newlander , Stuart Romeril , Meagan B. Rouse , Xinrong Tian , Sharad Kumar Verma
发明人: James Brackley, III , Joelle Lorraine Burgess , Seth Grant , Neil Johnson , Steven D. Knight , Louis Lafrance , William H. Miller , Kenneth Newlander , Stuart Romeril , Meagan B. Rouse , Xinrong Tian , Sharad Kumar Verma
IPC分类号: C07D401/14 , A61P35/00 , A61P35/02 , A61P37/06 , A61P37/00 , A61P31/10 , A61P19/02 , A61K31/496 , A61P1/00
CPC分类号: A61K31/496 , A61K31/405 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/5383 , A61K31/541 , A61K31/551 , C07D401/12 , C07D401/14 , C07D405/14 , C07D409/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/08 , C07D498/04
摘要: Herein are disclosed indoles of formula (I) where the various groups are defined herein, and which are useful in treating cancer.
摘要翻译: 本文公开了式(I)的吲哚,其中各种基团在本文中定义,并且其可用于治疗癌症。
-
公开(公告)号:US20060189511A1
公开(公告)日:2006-08-24
申请号:US10514338
申请日:2003-05-13
申请人: Holly Koblish , Carl Manthey , Christopher Molly , Tianbao Lu , Daniel Parks , Louis Lafrance , Karen Milkiewicz , Theodore Carver , Bruce Grasberger
发明人: Holly Koblish , Carl Manthey , Christopher Molly , Tianbao Lu , Daniel Parks , Louis Lafrance , Karen Milkiewicz , Theodore Carver , Bruce Grasberger
CPC分类号: A61K31/5513
摘要: The present invention is directed to a method of protecting one or more cells from programmed cytotoxic cell death by contacting the cells with a cytoprotective amount of an MDM2 and/or HDM2 inhibitor. The cytoprotective amount of inhibitor is typically used as a pulsed administration. Useful inhibitors include a class of 1,4-benzodiazepines, which act as inhibitors of MDM2-p53 interactions. The method of the invention can be employed as an adjunct to chemotherapy or radiation therapy. In addition, the methods of the invention can be employed to treat a disease or condition that involves excessive cell death.
摘要翻译: 本发明涉及通过使细胞与细胞保护剂量的MDM2和/或HDM2抑制剂接触来保护一种或多种细胞免受程序性细胞毒性细胞死亡的方法。 抑制剂的细胞保护量通常用作脉冲给药。 有用的抑制剂包括一类1,4-苯二氮卓类,其作为MDM2-p53相互作用的抑制剂。 本发明的方法可以用作化疗或放射治疗的辅助物质。 此外,本发明的方法可用于治疗涉及过度细胞死亡的疾病或病症。
-
公开(公告)号:US20060148792A1
公开(公告)日:2006-07-06
申请号:US11371964
申请日:2006-03-09
申请人: Tianbao Lu , Louis LaFrance , Daniel Parks , Karen Milkiewicz , Raul Calvo , Maxwell Cummings , Alexander Kim , Bruce Grasberger , Theodore Carver
发明人: Tianbao Lu , Louis LaFrance , Daniel Parks , Karen Milkiewicz , Raul Calvo , Maxwell Cummings , Alexander Kim , Bruce Grasberger , Theodore Carver
IPC分类号: A61K31/551 , C07D243/12 , C07D243/18
CPC分类号: C07D401/04 , C07D243/14 , C07D403/10 , C07D405/04 , C07D409/04
摘要: The present invention is directed to novel 1,4-benzodiazepines, pharmaceutical compositions thereof, and the use thereof as inhibitors of HDM2-p53 interactions. Compounds have Formula I: or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein: X and Y are independently —C(O)—, —CH2— or —C(S)—; R1, R2, R3, R4, R7, R8, Rb, Rc, Rd and M arm defined herein; R5 is hydrogen, alkyl, cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, optionally substituted heteroaralkyl, carboxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl, alkylaminocarbonyl or alkylaminocarbonylalkyl; R6 is cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, aralkyl, heteroarylalkyl, or a saturated or partially unsaturated heterocycle, each of which is optionally substituted; R9 is cycloalkyl: aryl, heteroaryl, a saturated or partially unsaturated heterocycle, cycloalkyl(alkyl), aralkyl or heteroarylalkyl, each of which is optionally substituted; and R10 is —(CH2)n—CO2Rb, —(CH2)m—CO2M, —(CH2)i—OH or —(CH2)j—CONRcRd n is 0-8, m is 0-8, i is 1-8 and j is 0-8.
摘要翻译: 本发明涉及新的1,4-苯二氮卓类药物,其药物组合物及其作为HDM2-p53相互作用抑制剂的用途。 化合物具有式I:或其溶剂合物,水合物或其药学上可接受的盐; 其中:X和Y独立地为-C(O) - , - CH 2 - 或-C(S) - ; R 1,R 2,R 3,R 4,R 7, R 8,R b,R c,R d,R d和M臂; R 5是氢,烷基,环烷基,任选取代的芳基,任选取代的杂芳基,任选取代的芳烷基,任选取代的杂芳烷基,羧基烷基,烷氧基羰基,烷氧基羰基烷基,氨基羰基,氨基羰基烷基,烷基氨基羰基或烷基氨基羰基烷基; R 6是环烷基,芳基,杂芳基,环烷基烷基,芳烷基,杂芳基烷基或饱和或部分不饱和的杂环,其各自任选被取代; R 9是环烷基:芳基,杂芳基,饱和或部分不饱和的杂环,环烷基(烷基),芳烷基或杂芳基烷基,其各自任选被取代; 和R 10是 - (CH 2)n - - - - - - (CH 2)n - , - (CH 2)2 - , - M 2 - , - (CH 2) -OH或 - (CH 2 CH 2)n -CONR C n R n为0-8 ,m为0-8,i为1-8,j为0-8。
-
公开(公告)号:US08846935B2
公开(公告)日:2014-09-30
申请号:US13696436
申请日:2011-05-05
申请人: Celine Duquenne , Neil Johnson , Steven D. Knight , Louis Lafrance , William H. Miller , Kenneth Newlander , Stuart Romeril , Meagan B. Rouse , Xinrong Tian , Sharad Kumar Verma
发明人: Celine Duquenne , Neil Johnson , Steven D. Knight , Louis Lafrance , William H. Miller , Kenneth Newlander , Stuart Romeril , Meagan B. Rouse , Xinrong Tian , Sharad Kumar Verma
IPC分类号: C07D401/00 , C07D405/00 , C07D231/56
CPC分类号: C07D409/14 , C07D401/12 , C07D401/14 , C07D471/04
摘要: Herein are disclosed indazoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
摘要翻译: 本文公开了式(I)的吲唑,其中各种基团在本文中定义,并且其可用于治疗癌症。
-
公开(公告)号:US20060235007A1
公开(公告)日:2006-10-19
申请号:US11452861
申请日:2006-06-14
申请人: Tianbao Lu , Karen Milkiewicz , Pierre Raboisson , Maxwell Cummings , Raul Calvo , Daniel Parks , Louis LaFrance , Juan Marugan Sanchez , Joan Gushue , Kristi Leonard
发明人: Tianbao Lu , Karen Milkiewicz , Pierre Raboisson , Maxwell Cummings , Raul Calvo , Daniel Parks , Louis LaFrance , Juan Marugan Sanchez , Joan Gushue , Kristi Leonard
IPC分类号: A61K31/5513 , C07D403/02 , C07D413/02 , C07D243/18
CPC分类号: C07D243/14
摘要: The present invention is directed to novel 1,4-diazepines, pharmaceutical compositions thereof and the use thereof as inhibitors of HDM2-p53 interactions. Compounds have Formula I: or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein: R1, R2, R9, R10, Ra, Rd and M are defined herein; X is a bivalent radical of: an alkane, a cycloalkane, an optionally-substituted arene, an optionally-substituted heteroarene, an optionally-substituted arylalkane or an optionally-substituted heteroarylalkane; and R3 is —CO2Rd, —CO2M, —OH, —NHRd, —SO2Rd, —NHCONHRd, optionally-substituted amidino or optionally-substituted guanidino; or R3—X— is hydrogen or an electron pair; R4 is oxygen or —NR9R10; R5 is cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, aralkyl, heteroarylalkyl, or a saturated or partially unsaturated heterocycle, each of which is optionally substituted; and R6, R7 and R8 are independently hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, a saturated or partially unsaturated heterocycle, cycloalkylalkyl, aralkyl or heteroarylalkyl, each of which is optionally substituted; or R6 and R7, together with the carbon atom to which they are attached form a 3- to 7-membered carbocyclic ring optionally substituted 1 to 3 times with Ra.
摘要翻译: 本发明涉及新的1,4-二氮杂,其药物组合物及其作为HDM2-p53相互作用抑制剂的用途。 化合物具有式I:或其溶剂合物,水合物或其药学上可接受的盐; 其中:R 1,R 2,R 9,R 10,R SUP, >,R d和M在本文中定义; X是二价基团:烷烃,环烷烃,任选取代的芳烃,任选取代的杂芳烃,任选取代的芳基烷烃或任选取代的杂芳基烷烃; 和R 3是-CO 2 R 2,-CO 2 M,-OH,-NHR 0 任选取代的脒基或任选取代的胍基;其中R 1,R 2,R 3,R 4, 或R 3 -X-是氢或电子对; R 4是氧或-NR 9 R 10; R 5是环烷基,芳基,杂芳基,环烷基烷基,芳烷基,杂芳基烷基或饱和或部分不饱和的杂环,其各自任选被取代; R 6和R 8独立地是氢,烷基,环烷基,芳基,杂芳基,饱和或部分不饱和的杂环,环烷基烷基 ,芳烷基或杂芳基烷基,其各自任选被取代; 或R 6和R 7与它们所连接的碳原子一起形成3-至7-元碳环,任选地被R 1取代1至3倍, SUP> a SUP>。
-
公开(公告)号:US20130059849A1
公开(公告)日:2013-03-07
申请号:US13696601
申请日:2011-05-05
申请人: Joelle Lorraine Burgess , Neil Johnson , Steven D. Knight , Louis Lafrance , William H. Miller , Kenneth Newlander , Stuart Romeril , Meagan B. Rouse , Xinrong Tian , Sharad Kumar Verma , Dominic Suarez
发明人: Joelle Lorraine Burgess , Neil Johnson , Steven D. Knight , Louis Lafrance , William H. Miller , Kenneth Newlander , Stuart Romeril , Meagan B. Rouse , Xinrong Tian , Sharad Kumar Verma , Dominic Suarez
IPC分类号: A61K31/444 , A61P35/00 , A61K31/506 , A61K31/5377 , A61K31/496 , A61K31/513 , C07D471/04 , A61K31/4545
CPC分类号: C07D471/04 , C07D519/00
摘要: Herein are disclosed azaindazoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
摘要翻译: 本文公开了式(I)的氮杂吲唑,其中各种基团在本文中定义,并且其可用于治疗癌症。
-
公开(公告)号:US20130053383A1
公开(公告)日:2013-02-28
申请号:US13696436
申请日:2011-05-05
申请人: Celine Duquenne , Neil Johnson , Steven D. Knight , Louis Lafrance , William H. Miller , Kenneth Newlander , Stuart Romeril , Meagan B. Rouse , Xinrong Tian , Sharad Kumar Verma
发明人: Celine Duquenne , Neil Johnson , Steven D. Knight , Louis Lafrance , William H. Miller , Kenneth Newlander , Stuart Romeril , Meagan B. Rouse , Xinrong Tian , Sharad Kumar Verma
IPC分类号: A61K31/4439 , A61P35/00 , A61P35/02 , C07D401/14 , A61K31/4545 , A61K31/496 , A61K31/506 , C07D413/14 , A61K31/5377 , C07D409/14 , C07D401/12 , A61K31/444
CPC分类号: C07D409/14 , C07D401/12 , C07D401/14 , C07D471/04
摘要: Herein are disclosed indazoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
摘要翻译: 本文公开了式(I)的吲唑,其中各种基团在本文中定义,并且其可用于治疗癌症。
-
公开(公告)号:US20070219233A1
公开(公告)日:2007-09-20
申请号:US11755831
申请日:2007-05-31
申请人: Tianbo Lu , Bruce Tomczuk , Louis LaFrance , Thomas Markotan , Juan Marugan Sanchez , Victor Marder , David U'Prichard , Beth Anaclerio , Zihong Guo , Wenzi Pan , Kristi Leonard
发明人: Tianbo Lu , Bruce Tomczuk , Louis LaFrance , Thomas Markotan , Juan Marugan Sanchez , Victor Marder , David U'Prichard , Beth Anaclerio , Zihong Guo , Wenzi Pan , Kristi Leonard
IPC分类号: A61K31/4353 , C07D471/04
CPC分类号: C07D213/74 , C07D209/08 , C07D401/12 , C07D401/14 , C07D471/02 , C07D471/04 , C07D471/14
摘要: The present invention relates to novel substituted indole compounds that are antagonists of alpha V (αv) integrins, for example αvβ3 and αvβ5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment of pathological conditions mediated by αvβ3 and αvβ5 integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula: where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, D, X, W, a, m, n, i, j, k and v are defined herein.
摘要翻译: 本发明涉及作为αV(alphav)整联蛋白的拮抗剂的新的取代的吲哚化合物,例如α缬氨酸和/ β5整联蛋白,其药学上可接受的盐及其药物组合物。 该化合物可用于治疗由α3β3和α5β5 5介导的病理状况。 整合素,包括肿瘤生长,转移,再狭窄,骨质疏松症,炎症,黄斑变性,糖尿病性视网膜病变和类风湿性关节炎等病症。 化合物具有以下通式:其中R 1,R 2,R 3,R 4,R 4, R 5,R 6,R 7,R 8,R 9,R 9, D 10,R 11,R 12,R 13,R 14,D, X,W,a,m,n,i,j,k和v在本文中定义。
-
公开(公告)号:US20050250771A1
公开(公告)日:2005-11-10
申请号:US11005294
申请日:2004-12-06
申请人: Tianbo Lu , Bruce Tomczuk , Louis LaFrance , Thomas Markotan , Juan Marugan Sanchez , Victor Marder , David U'Prichard , Beth Anaclerio , Zihong Guo , Wenzi Pan , Kristi Leonard
发明人: Tianbo Lu , Bruce Tomczuk , Louis LaFrance , Thomas Markotan , Juan Marugan Sanchez , Victor Marder , David U'Prichard , Beth Anaclerio , Zihong Guo , Wenzi Pan , Kristi Leonard
IPC分类号: A61K31/404 , A61K31/4375 , A61K31/4439 , A61K31/4709 , A61K31/5383 , A61P3/06 , A61P3/10 , A61P7/06 , A61P9/00 , A61P9/10 , A61P19/10 , A61P25/00 , A61P25/04 , A61P25/08 , A61P25/18 , A61P25/22 , A61P27/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D209/08 , C07D213/74 , C07D401/12 , C07D401/14 , C07D403/12 , C07D471/04 , C07D498/04 , A61K31/538 , A61K31/405 , A61K31/4745 , A61K31/506 , C07D413/02 , C07D43/02
CPC分类号: C07D213/74 , C07D209/08 , C07D401/12 , C07D401/14 , C07D471/02 , C07D471/04 , C07D471/14
摘要: The present invention relates to novel substituted indole compounds that are antagonists of alpha V (αv) integrins, for example αvβ3 and αvβ5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment of pathological conditions mediated by αvβ3 and αvβ5 integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula: where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, , R12, R13, R14, D, X, W, a, m, n, i, j, k and v are defined herein.
摘要翻译: 本发明涉及作为αV(alphav)整联蛋白拮抗剂的新型取代的吲哚化合物,例如阿尔茨海默氏症和/ 整联蛋白,其药学上可接受的盐及其药物组合物。 该化合物可用于治疗由α3β3和α5β5 5介导的病理状况。 整合素,包括肿瘤生长,转移,再狭窄,骨质疏松症,炎症,黄斑变性,糖尿病性视网膜病变和类风湿性关节炎等病症。 化合物具有以下通式:其中R 1,R 2,R 3,R 4,R 4, R 5,R 6,R 7,R 8,R 9,R 9, R 10,R 11,R 12,R 12,R 14,D 12, ,X,W,a,m,n,i,j,k和v在本文中定义。
-
公开(公告)号:US20050209225A1
公开(公告)日:2005-09-22
申请号:US11005596
申请日:2004-12-06
申请人: Tianbao Lu , Louis LaFrance , Bruce Tomczuk , Thomas Markotan , Juan Marugan Sanchez , Victor Marder , David U'Prichard , Beth Anaclerio , Zihong Guo , Wenzi Pan , Kristi Leonard
发明人: Tianbao Lu , Louis LaFrance , Bruce Tomczuk , Thomas Markotan , Juan Marugan Sanchez , Victor Marder , David U'Prichard , Beth Anaclerio , Zihong Guo , Wenzi Pan , Kristi Leonard
IPC分类号: A61K31/404 , A61K31/4375 , A61K31/4439 , A61K31/4709 , A61K31/5383 , A61P3/06 , A61P3/10 , A61P7/06 , A61P9/00 , A61P9/10 , A61P19/10 , A61P25/00 , A61P25/04 , A61P25/08 , A61P25/18 , A61P25/22 , A61P27/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D209/08 , C07D213/74 , C07D401/12 , C07D401/14 , C07D403/12 , C07D471/04 , C07D498/04 , A61K31/538 , A61K31/405 , A61K31/4745 , A61K31/506
CPC分类号: C07D213/74 , C07D209/08 , C07D401/12 , C07D401/14 , C07D471/02 , C07D471/04 , C07D471/14
摘要: The present invention relates to novel substituted indole compounds that are antagonists of alpha V (αv) integrins, for example αvβ3 and αvβ5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment of pathological conditions mediated by αvβ3 and αvβ5 integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula: where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, D, X, W, a, m, n, i, j, k and v are defined herein.
摘要翻译: 本发明涉及作为αV(alphav)整联蛋白的拮抗剂的新的取代的吲哚化合物,例如α缬氨酸和/ β5整联蛋白,其药学上可接受的盐及其药物组合物。 该化合物可用于治疗由α3β3和α5β5 5介导的病理状况。 整合素,包括肿瘤生长,转移,再狭窄,骨质疏松症,炎症,黄斑变性,糖尿病性视网膜病变和类风湿性关节炎等病症。 化合物具有以下通式:其中R 1,R 2,R 3,R 4,R 4, R 5,R 6,R 7,R 8,R 9,R 9, D 10,R 11,R 12,R 13,R 14,D, X,W,a,m,n,i,j,k和v在本文中定义。
-
-
-
-
-
-
-
-
-